The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics

- The 3 clinical trials can't be compared effectively because of concrete differences.
- Bevacizumab (beva) is non-toxic as monotherapy and is a chemosensitizer.
- Combining bevacizumab and highly toxic doses of chemotherapy masks beva's efficacy.
- Re-evaluate the current model of highly toxic doses of chemo with bevacizumab.
- Metronomic dosing (frequent lower doses of chemo) with beva may be more effective.